Aguirre-Vidal Yoshajandith, Montes Sergio, Mota-López Ana Carolina, Navarrete-Vázquez Gabriel
Red de Estudios Moleculares Avanzados, Campus III, Instituto de Ecología A.C. (INECOL), Xalapa, 91073 Veracruz, Mexico.
Unidad Académica Multidisciplinaria, Reynosa-Aztlan, Reynosa 88740, Tamaulipas, Mexico.
Clin Park Relat Disord. 2024 Jul 18;11:100265. doi: 10.1016/j.prdoa.2024.100265. eCollection 2024.
This review explores the intricate connections between type 2 diabetes (T2D) and Parkinson's disease (PD), both prevalent chronic conditions that primarily affect the aging population. These diseases share common early biochemical pathways that contribute to tissue damage. This manuscript also systematically compiles potential shared cellular mechanisms between T2D and PD and discusses the literature on the utilization of antidiabetic drugs as potential therapeutic options for PD. This review encompasses studies investigating the experimental and clinical efficacy of antidiabetic drugs in the treatment of Parkinson's disease, along with the proposed mechanisms of action. The exploration of the benefits of antidiabetic drugs in PD presents a promising avenue for the treatment of this neurodegenerative disorder.
本综述探讨了2型糖尿病（T2D）与帕金森病（PD）之间的复杂联系，这两种都是主要影响老年人群的常见慢性病。这些疾病具有共同的早期生化途径，会导致组织损伤。本手稿还系统地汇编了T2D和PD之间潜在的共同细胞机制，并讨论了将抗糖尿病药物用作PD潜在治疗选择的相关文献。本综述涵盖了研究抗糖尿病药物治疗帕金森病的实验和临床疗效以及所提出的作用机制的研究。探索抗糖尿病药物在PD中的益处为治疗这种神经退行性疾病提供了一条有前景的途径。
